-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $321

Benzinga·11/05/2026 19:50:35
Listen to the news
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $260 to $321.